These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18045949)

  • 1. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy.
    Riesco-Eizaguirre G; Santisteban P
    Endocr Relat Cancer; 2007 Dec; 14(4):957-77. PubMed ID: 18045949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer.
    Couto JP; Prazeres H; Castro P; Lima J; Máximo V; Soares P; Sobrinho-Simões M
    J Clin Pathol; 2009 May; 62(5):414-21. PubMed ID: 19147628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic mutations in thyroid carcinoma.
    Taccaliti A; Boscaro M
    Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular mechanism of thyroid carcinogenesis].
    Yamashita S; Mitsutake N
    Nihon Rinsho; 2007 Nov; 65(11):1959-65. PubMed ID: 18018555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathogenesis of follicular cell derived thyroid cancers.
    Parameswaran R; Brooks S; Sadler GP
    Int J Surg; 2010; 8(3):186-93. PubMed ID: 20097316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations.
    Salvatore G; Chiappetta G; Nikiforov YE; Decaussin-Petrucci M; Fusco A; Carney JA; Santoro M
    Eur J Cancer; 2005 Mar; 41(5):816-21. PubMed ID: 15763659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy: a new hope for thyroid carcinomas.
    Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.
    Kojic KL; Kojic SL; Wiseman SM
    Expert Rev Anticancer Ther; 2012 Mar; 12(3):345-57. PubMed ID: 22369326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Genetic abnormality in thyroid cancers].
    Yamashita S
    Nihon Rinsho; 2005 Oct; 63 Suppl 10():159-62. PubMed ID: 16279621
    [No Abstract]   [Full Text] [Related]  

  • 10. New molecular targeted therapies in thyroid cancer.
    Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
    Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
    McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
    Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gene abnormalities in thyroid cancer].
    Namba H; Yamashita S
    Nihon Rinsho; 2007 Nov; 65(11):1967-72. PubMed ID: 18018556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.
    Santoro M; Carlomagno F
    Nat Clin Pract Endocrinol Metab; 2006 Jan; 2(1):42-52. PubMed ID: 16932252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications.
    Omar E; Madhavan M; Othman NH
    Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular events in follicular thyroid tumors.
    Kroll TG
    Cancer Treat Res; 2004; 122():85-105. PubMed ID: 16209039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathological and clinical features of malignant thyroid tumors: classification, immunohistology, prognostic criteria].
    Schröder S
    Veroff Pathol; 1988; 130():1-159. PubMed ID: 3213226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.
    Lubitz CC; Sadow PM; Daniels GH; Wirth LJ
    Thyroid; 2021 Oct; 31(10):1451-1462. PubMed ID: 33860688
    [No Abstract]   [Full Text] [Related]  

  • 19. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
    Fagin JA
    J Endocrinol; 2004 Nov; 183(2):249-56. PubMed ID: 15531713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling anaplastic thyroid carcinoma in the mouse.
    Champa D; Di Cristofano A
    Horm Cancer; 2015 Feb; 6(1):37-44. PubMed ID: 25420535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.